Geneva form 1 ranitidine, Ivax terfenadine ANDAs tentatively approved.
Executive Summary
GENEVA RANITIDINE FORM 1 ANDA TENTATIVE APPROVAL JAN. 31 is the first for that version of Glaxo Wellcome's anti-ulcer agent Zantac. Glaxo's GATT-extended patent term expires in July 1997. Glaxo has never marketed form 1 ranitidine and claims Zantac is protected through 2002 by a patent for form 2 ranitidine.